InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List

BEIJING, Dec. 3, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug...

Full "IntellAsia: Resources" article